Ferrous bisglycinate, a dietary supplement form of iron bound to the amino acid glycine, is used to treat low iron. In people truly low in iron, strong evidence shows it corrects deficiency and anemia, with fewer digestive side effects at the lower doses it allows. With adequate iron, no evidence shows benefit for health or lifespan, and unneeded use can lead to iron accumulation the body cannot remove. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Ferritin | Above 45 µg/L; below 200 µg/L (premenopausal women) or 300 µg/L (men, postmenopausal women) | Expected to change; safety check for overload |
| Transferrin saturation | Below 45% (premenopausal women) or 50% (men, postmenopausal women) | Safety check for overload |
| Hemoglobin | 13.5–17.5 g/dL (men); 12.0–15.5 g/dL (women) | Expected to change; confirms response |
| CRP | Not specified in the ER | Inflammation falsely raises ferritin |
| MCV | Not specified in the ER | Normalizes as deficiency resolves |
| TSH (levothyroxine users only) | 0.4–4.0 mU/L | Signals the iron–levothyroxine interaction |
Cadence: Baseline before starting; repeat at 4 weeks, then at 8–12 weeks, then every 6–12 months for maintenance users; TSH 6–8 weeks after starting iron